AARD Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aardvark Therapeutics Securities Lawsuit - Contact SueWallSt

Barchart · 1d ago

A securities class action alleges Aardvark Therapeutics overstated ARD-101's safety profile; Wall Street price targets collapsed from as high as $29 to $7 after the Phase 3 HERO trial was paused and the FDA imposed a clinical hold.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.